Comparison of pain relieving efficacy of Dexmedetomidine, Fentanyl and Dexamethasone as an adjuvant to Ropivacaine in above the Collar bone Brachial plexus block (USG guided) when administered perineurally in adult patients undergoing upper limb surgery .

Comparison of analgesic efficacy of Dexmedetomidine, Fentanyl and Dexamethasone as an adjuvant to Ropivacaine in Supraclavicular Brachial plexus block (USG guided) when administered perineurally in adult patients undergoing upper limb surgery : A randomized comparative study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027358

Enrollment

Registered

2020-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Control Intervention1: Ropivacaine Dexmedetomidine Dexamethasone fentanyl : Ropivacaine 0.5% 30ML with Dexmedetomidine 100 mcg Ropivacaine 0.5% 30ML with Dexamethasone 8 mg Ropivacaine 0.5% 30ML w

Eligibility

Inclusion criteria

Inclusion criteria: All patients aged 20 to 60 years of either gender of ASA physical statue I and II undergoing upper limb surgery who willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patient refusal, 2. Hypersensitivity to amide local anaesthetics according to past history 3. Hypersensitivity to fentanyl, dexamethasone, dexmedatomidine infection at the injection site 4. Pregnant woman ( Urine Pregnancy Test positive) 5. Obesity (BMI >30kg/m2 ) 6. Uncooperative patients 7. Anatomical abnormality at the site of injection 8. Bleeding disorders ( Deranged PT-INR , Clotting time and Bleeding time) 9. Peripheral neuropathy or neurological deficit ( Based on history of neurological disease and Clinical Neurological assessment- Fine Touch, Pin Test, Motor power) 10. Concurrent chronic analgesic therapy 11. Known hepatic or renal insufficiency( Deranged LFT, SGOT, SGPT, Serum Creatinine, Blood Urea) 12. Field block1. Patient refusal, 2. Hypersensitivity to amide local anaesthetics according to past history 3. Hypersensitivity to fentanyl, dexamethasone, dexmedatomidine infection at the injection site 4. Pregnant woman ( Urine Pregnancy Test positive) 5. Obesity (BMI >30kg/m2 ) 6. Uncooperative patients 7. Anatomical abnormality at the site of injection 8. Bleeding disorders ( Deranged PT-INR , Clotting time and Bleeding time) 9. Peripheral neuropathy or neurological deficit ( Based on history of neurological disease and Clinical Neurological assessment- Fine Touch, Pin Test, Motor power) 10. Concurrent chronic analgesic therapy 11. Known hepatic or renal insufficiency( Deranged LFT, SGOT, SGPT, Serum Creatinine, Blood Urea) 12. Field block failure. failure.

Design outcomes

Primary

Measure	Time frame
To compare the duration of analgesia produced in all three groups.Timepoint: VAS Score analysis,blood pressure and heart rate before the procedure ,at the time of procedure and then every five minutes after the procedure.	—

Secondary

Measure	Time frame
1) Onset of sensory block in minutes after the completion of block 2)Onset of motor block in minutes after the completion of block 3)Duration of motor block in hours until return of motor power 3)Haemodynamic parameters (heart rate, blood pressure,spo2)Timepoint: VAS Score analysis,blood pressure and heart rate before the procedure ,at the time of procedure and then every five minutes after the procedure.	—

Measure

Time frame

1) Onset of sensory block in minutes after the completion of block 2)Onset of motor block in minutes after the completion of block 3)Duration of motor block in hours until return of motor power 3)Haemodynamic parameters (heart rate, blood pressure,spo2)Timepoint: VAS Score analysis,blood pressure and heart rate before the procedure ,at the time of procedure and then every five minutes after the procedure.

—

Countries

India

Contacts

Public ContactPradeep Kumar Mulewa

Dr S. N Medical College, Jodhpur

drvikasrajpurohit@gmail.com9928060011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026